Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $CDTX
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP |
1/27/2025 | Overweight | Cantor Fitzgerald | |
12/13/2024 | $34.00 | Outperform | RBC Capital Mkts |
11/8/2024 | $33.00 | Buy | Guggenheim |
8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
12/3/2021 | $6.00 | Buy | H.C. Wainwright |
9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
9/22/2021 | $6.25 | Buy → Strong Buy | WBB Securities |
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the "Other pharmaceuticals as preventive tools" panel at a World Health Organization (WHO) global meeting on H5N1 influenza preparedness and response. The meeting, titled "What research is important to prepare and respond to H5N1 influenza outbreaks," will be held virtually on March 19, 2025, from 1:00-7:15pm Central European Time (CET)/5:00-11:15am Pacific Time (PT), and the panel discussion will take place from 6:30-7:00 pm CET/10:30-11:00am PT. "Globa
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR). The conference takes place from March 17-21, 2025 in Las Vegas, Nevada. Cidara's presentations will highlight the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for evaluation of CD388 in a Phase 3 study. Presentation details: Title: NAVIGATE: A Phase 2b, Randomized, Doub
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced the publication of preclinical data assessing CD388, the company's influenza DFC, in the peer-reviewed scientific journal Nature Microbiology. The article, entitled "Drug-Fc Conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice," highlights the potential of CD388 as a potent, universal preventative for influenza A and
Citizens JMP initiated coverage on Cidara Therapeutics with a new price target
Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00
Cantor Fitzgerald resumed coverage on Cidara Therapeutics
Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight
RBC Capital Mkts initiated coverage on Cidara Therapeutics with a new price target
RBC Capital Mkts initiated coverage of Cidara Therapeutics with a rating of Outperform and set a new price target of $34.00
President & CEO Stein Jeffrey bought $105,680 worth of shares (8,000 units at $13.21) (SEC Form 4)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
COO & CLO Ward Shane sold $36,542 worth of shares (1,664 units at $21.96), decreasing direct ownership by 10% to 14,674 units (SEC Form 4)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
CHIEF SCIENTIFIC OFFICER Tari Leslie sold $38,940 worth of shares (1,773 units at $21.96), decreasing direct ownership by 10% to 16,215 units (SEC Form 4)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
Chief Financial Officer Karbe Frank was granted 57,500 shares (SEC Form 4)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
SEC Form S-8 filed by Cidara Therapeutics Inc.
S-8 - Cidara Therapeutics, Inc. (0001610618) (Filer)
Cidara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
SEC Form 10-K filed by Cidara Therapeutics Inc.
10-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP to its Scientific Advisory Board (SAB). "We are honored that these four esteemed physicians and scientists have agreed to join our Scientific Advisory Board," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They have already provided i
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validationMelinta acquires exclusive rights to commercialize rezafungin in the U.S.Cidara to receive up to $460 million, with an upfront cash payment of $30 million, $60 million in regulatory milestones, and up to $370 million in commercial milestones, plus tiered low double digits to mid-teens royalties on net salesCidara to focus on advancing Cloudbreak DFC platform in oncology and viral infections SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and
SEC Form SC 13G filed by Cidara Therapeutics Inc.
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SEC Form SC 13G filed by Cidara Therapeutics Inc.
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SEC Form SC 13G filed by Cidara Therapeutics Inc.
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)